Imatinib augments standard malaria combination therapy without added toxicity

To egress from its erythrocyte host, the malaria parasite, Plasmodium falciparum, must destabilize the erythrocyte membrane by activating an erythrocyte tyrosine kinase. Because imatinib inhibits erythrocyte tyrosine kinases and because imatinib has a good safety profile, we elected to determine whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Huynh Dinh, Pantaleo, Antonella, Kesely, Kristina R., Noomuna, Panae, Putt, Karson S., Tuan, Tran Anh, Low, Philip S., Turrini, Francesco M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Brief Definitive Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404470/
https://www.ncbi.nlm.nih.gov/pubmed/34436509
http://dx.doi.org/10.1084/jem.20210724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404470/
https://www.ncbi.nlm.nih.gov/pubmed/34436509
http://dx.doi.org/10.1084/jem.20210724

Ejemplares similares